Efficacy and Safety of Taeeumjowi-tang in Obese Korean Adults: A Double-Blind, Randomized, and Placebo-Controlled Pilot Trial

Table 3

Analyses of lipid profile, body fat composition, and CRP.

Secondary outcomes (lipid profile, body fat composition, and CRP)	Period	Group				𝑃^∗	(𝑃inter)
		Placebo group (𝑁=55)		TJ001 group (𝑁=57)
		Mean ± S.D.	(𝑃intra)	Mean ± S.D.	(𝑃intra)
Lipid profile
Cholesterol
Total cholesterol, mg/dL	Baseline	207.3±36.8	0.1142	191.7±31.5	0.0983	0.0180	0.8980
	week 12	201.9±39.6		187.2±34.3		0.0374
HDL cholesterol, mg/dL	Baseline	46.9±9.90	0.8695	46.1±10.6	0.7240	0.7161	0.2717
	week 12	47.2±10.9		45.9±9.70		0.5249
Triglyceride, g/dL	Baseline	152.2±87.2	0.4709	134.6±66.9	0.8306	0.2352	0.4977
	week 12	143.3±87.9		133.3±64.5		0.4963
Body fat composition
Total fat area (TFA), cm^2	Baseline	402.8±153.9	0.2103	392.5±134.6	0.1201	0.7105	0.5205
	week 12	387.9±134.2		383.4±137.0		0.8601
Visceral fat area (VFA), cm^2	Baseline	118.2±58.1	0.4255	110.1±47.0	0.2669	0.4252	0.6621
	week 12	115.9±58.5		105.4±51.8		0.3253
Subcutaneous fat area (SFA), cm^2	Baseline	283.6±116.3	0.2898	282.1±103.0	0.2582	0.9425	0.3767
	week 12	272.1±102.1		278.2±105.2		0.7579
VFA/SFA	Baseline	0.44±0.21	0.3921	0.40±0.17	0.5682	0.2524	0.8109
	week 12	0.43±0.21		0.39±0.19		0.3055
C-reactive protein (CRP), mg/dL	Baseline	0.83±0.17	0.3766	0.78±0.18	0.6834	0.1547	0.3731
	week 12	0.85±0.19		0.79±0.19		0.0721

𝑃^∗: A 𝑃 value for between-group comparison at each visit and visit X group interaction using ANOVA.
(𝑃_intra): A 𝑃 value for within-group comparison between baseline and 5th visit by paired 𝑡-test.
(𝑃_inter): A 𝑃 value for between-group comparison after 12-week treatment using ANCOVA (baseline as covariate).
𝑃<0.05 were considered statistically significant.